Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has received a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $35.40.

A number of equities research analysts recently commented on LENZ shares. Raymond James initiated coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 target price for the company. Piper Sandler restated an “overweight” rating and set a $36.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Finally, William Blair upgraded shares of LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th.

Hedge Funds Weigh In On LENZ Therapeutics

A number of large investors have recently bought and sold shares of LENZ. American International Group Inc. purchased a new position in LENZ Therapeutics during the first quarter valued at $44,000. SG Americas Securities LLC acquired a new position in shares of LENZ Therapeutics during the 3rd quarter worth about $107,000. MetLife Investment Management LLC purchased a new position in LENZ Therapeutics in the 3rd quarter valued at about $182,000. GSA Capital Partners LLP acquired a new stake in LENZ Therapeutics in the 3rd quarter worth about $246,000. Finally, Squarepoint Ops LLC purchased a new stake in LENZ Therapeutics during the 2nd quarter worth approximately $181,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Price Performance

NASDAQ:LENZ opened at $35.50 on Wednesday. LENZ Therapeutics has a twelve month low of $14.42 and a twelve month high of $38.93. The company’s 50 day moving average is $27.29 and its two-hundred day moving average is $22.59.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same quarter in the previous year, the business earned ($1.33) EPS. As a group, research analysts forecast that LENZ Therapeutics will post -2.09 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.